Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

Demand for cosmetic procedures to fix Sydneysiders’ saggy skin and lost facial fat associated with weight-loss drugs has ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Omada Health is making its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...